CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 156 enrolled
Drug / intervention
SHR-1210drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03558191
NCT03558191Phase 2Completed
CompareCT.gov

A Single-arm, Open Label, Multi-center, Phase 2 Study of SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients Who Have Received Previous At Least Two Lines of Chemotherapy.

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Jun 15, 2018·Updated Mar 15, 2024

In Brief

A Phase 2 clinical trial evaluating SHR-1210 for Nasopharyngeal Carcinoma. Completed, enrolled 156 participants across 1 site.

Detailed Summary

This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 15, 2018
Enrollment StartAug 14, 2018
Primary CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.0 years ago

Interventions

SHR-1210drug

A humanized monoclonal immunoglobulin PD-1 antibody